
Randeep Singh
Examiner (ID: 177, Phone: (571)270-3881 , Office: P/1615 )
| Most Active Art Unit | 1615 |
| Art Unit(s) | 1615 |
| Total Applications | 524 |
| Issued Applications | 328 |
| Pending Applications | 7 |
| Abandoned Applications | 192 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18612387
[patent_doc_number] => 20230279119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => ANTIBODIES THAT BIND INTEGRIN AVB8 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/153103
[patent_app_country] => US
[patent_app_date] => 2023-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153103
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/153103 | Antibodies that bind integrin avb8 and uses thereof | Jan 10, 2023 | Issued |
Array
(
[id] => 18709238
[patent_doc_number] => 20230331851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 18/153277
[patent_app_country] => US
[patent_app_date] => 2023-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36909
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/153277 | Neutralizing antibodies to the avb8 integrin complex for immunotherapy | Jan 10, 2023 | Issued |
Array
(
[id] => 18550721
[patent_doc_number] => 20230248721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METHOD FOR DETECTING OR TREATING TRIPLE NEGATIVE BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 18/091145
[patent_app_country] => US
[patent_app_date] => 2022-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5871
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091145
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/091145 | Method for detecting or treating triple negative breast cancer | Dec 28, 2022 | Issued |
Array
(
[id] => 18484980
[patent_doc_number] => 20230212295
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => METHODS OF TREATMENT BY TARGETING VCAM1 AND MAEA
[patent_app_type] => utility
[patent_app_number] => 18/146951
[patent_app_country] => US
[patent_app_date] => 2022-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25918
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18146951
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/146951 | Methods of treatment by targeting VCAM1 and MAEA | Dec 26, 2022 | Issued |
Array
(
[id] => 18484947
[patent_doc_number] => 20230212261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/084618
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22620
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18084618
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/084618 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | Dec 19, 2022 | Abandoned |
| 18/009849 | ANTI-HUMAN INTERLEUKIN 23 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | Dec 11, 2022 | Pending |
Array
(
[id] => 18895242
[patent_doc_number] => 20240010727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/064663
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19416
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064663
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064663 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY | Dec 11, 2022 | Pending |
Array
(
[id] => 18420162
[patent_doc_number] => 20230174623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/056825
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056825
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/056825 | Collagen-localized immunomodulatory molecules and methods thereof | Nov 17, 2022 | Issued |
Array
(
[id] => 18675165
[patent_doc_number] => 20230312754
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => NOVEL PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/980751
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980751
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/980751 | Peptides | Nov 3, 2022 | Issued |
Array
(
[id] => 18346638
[patent_doc_number] => 20230134748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
[patent_app_type] => utility
[patent_app_number] => 17/980149
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34010
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980149
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/980149 | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody | Nov 2, 2022 | Pending |
Array
(
[id] => 18436069
[patent_doc_number] => 20230183363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => ANTI-NR10 ANTIBODY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/975865
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35730
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975865
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975865 | ANTI-NR10 ANTIBODY AND USE THEREOF | Oct 27, 2022 | Abandoned |
Array
(
[id] => 19354118
[patent_doc_number] => 12054549
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-06
[patent_title] => Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
[patent_app_type] => utility
[patent_app_number] => 18/050817
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 33944
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 289
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050817
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050817 | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders | Oct 27, 2022 | Issued |
Array
(
[id] => 18727124
[patent_doc_number] => 20230341406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => MEANS AND METHODS FOR TREATING ANGIOGENESIS-RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/965967
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17965967
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/965967 | Means and methods for treating angiogenesis-related diseases | Oct 13, 2022 | Issued |
Array
(
[id] => 18709216
[patent_doc_number] => 20230331828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => Anti-Abeta Antibodies
[patent_app_type] => utility
[patent_app_number] => 17/931386
[patent_app_country] => US
[patent_app_date] => 2022-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23843
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 208
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/931386 | Anti-Abeta Antibodies | Sep 11, 2022 | Abandoned |
Array
(
[id] => 20549824
[patent_doc_number] => 12560610
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-24
[patent_title] => Sparc assay
[patent_app_type] => utility
[patent_app_number] => 17/930548
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 4072
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930548
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930548 | Sparc assay | Sep 7, 2022 | Issued |
Array
(
[id] => 18077404
[patent_doc_number] => 20220403016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/930704
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930704
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930704 | ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF | Sep 7, 2022 | Pending |
Array
(
[id] => 18597305
[patent_doc_number] => 20230272100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => ANTIBODIES AGAINST OX-40 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/819287
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 93546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819287
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/819287 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | Aug 10, 2022 | Abandoned |
Array
(
[id] => 18497437
[patent_doc_number] => 20230220073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => ROR1 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/869872
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17869872
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/869872 | ROR1 ANTIBODIES | Jul 20, 2022 | Abandoned |
Array
(
[id] => 17990212
[patent_doc_number] => 20220356249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => HUMAN ANTI-SEMAPHORIN 4D ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/813375
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813375 | Human anti-semaphorin 4D antibody | Jul 18, 2022 | Issued |
Array
(
[id] => 18108096
[patent_doc_number] => 20230000976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
[patent_app_type] => utility
[patent_app_number] => 17/859996
[patent_app_country] => US
[patent_app_date] => 2022-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17859996
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/859996 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | Jul 6, 2022 | Abandoned |